12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PRIMA-1MET: Additional Phase I/II data

Additional data from an open-label, Swedish Phase I/II trial in 22 patients with refractory hematologic malignancies or prostate cancer showed that once-daily doses of up to 90 mg/kg IV APR-246 for 4 consecutive days were well tolerated with fatigue, dizziness, headache and confusion reported as the...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >